Nxera Pharma Welcomes New Leadership to Drive Global Growth

Nxera Pharma is making bold moves to strengthen its leadership team, welcoming Kiyoshi Kaneko as Chief Commercial Officer (CCO) and promoting Mariko Nakafuji to Chief Legal Officer (CLO). Kaneko, a seasoned executive with deep expertise in corporate strategy, business development, and marketing, has held key leadership roles at AstraZeneca Japan and Luye Life Sciences Group. His extensive background in building strategic partnerships and expanding market presence will be invaluable as Nxera continues to grow. Based in Japan, he will lead the company’s commercial strategy and drive business innovation.

Meanwhile, Nakafuji, who joined Nxera in 2021 as General Counsel, has been instrumental in major acquisitions, including the expansion into Japan and South Korea through the purchase of Idorsia Pharmaceuticals' regional businesses. With years of experience in corporate M&A and private equity at Deloitte LLP and Jones Day LLP, she is well-equipped to handle Nxera’s global legal affairs. Now stepping into the role of CLO, she will be based in the UK, ensuring strong legal governance and strategic oversight as Nxera scales internationally.